Masked Hypertension and Atherogenesis: The Impact of Apelin and Relaxin Plasma Levels

Journal of Clinical Hypertension

Volumn 15, Issue 5, 2013, Pages 333-336

  Papadopoulos, Dimitris P ^a   Mourouzis, Iordanis ^a   Faselis, Charles ^b   Perrea, Despina ^c   Makris, Thomas ^d   Tsioufis, Costas ^e   Papademetriou, Vasilios ^f  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d HELENA VENIZELOU HOSPITAL   (Greece)

^e Ipokratio Hospital   (Greece)

^f GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN; RELAXIN;

ADULT; ARTICLE; ATHEROGENESIS; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MASKED HYPERTENSION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MASKED HYPERTENSION; MIDDLE AGED; RELAXIN;

EID: 84876840302     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12075     Document Type: Article

References (38)

1. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368-2374.
2. McKay DW, Myers MG, Bolli P, Chockalingam A. Masked hypertension: a common but insidious presentation of hypertension. Can J Cardiol. 2006;22:617-620.
3. Mancia G, Sega R, Bravi C, et al. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens. 1995;13(12 Pt 1):1377-1390.
4. Waeber B. What is behind masked hypertension? Rev Med Suisse. 2005;1:2089-2091.
5. Pickering TG. Effects of stress and behavioral interventions in hypertension: what is masked hypertension? J Clin Hypertens (Greenwich). 2003;5:171-174.
6. Palatini P. Masked hypertension: how can the condition be detected? Blood Press Monit. 2004;9:297.
7. Mancia G, Carugo S, Grassi G, et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Hypertension. 2002;39:744-749.
8. Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population PAMELA Study. Circulation. 2001;104:1385-1392.
9. Tomiyama M, Horio T, Kamide K, et al. Reverse white-coat effect as an independent risk for left ventricular concentric hypertrophy in patients with treated essential hypertension. J Hum Hypertens. 2007;21:212-219.
10. Hara A, Ohkubo T, Kikuya M, et al. Detection of carotid atherosclerosis in individuals with masked hypertension and white-coat hypertension by self-measured blood pressure at home: the Ohasama Study. J Hypertens. 2007;25:321-327.
11. Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18:1422-1428.
12. Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47:846-853.
13. Tomiyama M, Horio T, Yoshii M, et al. Masked hypertension and target organ damage in treated hypertensive patients. Am J Hypertens. 2006;19:880-886.
14. Kato T, Horio T, Tomiyama M, et al. Reverse white-coat effect as an independent risk for microalbuminuria in treated hypertensive patients. Nephrol Dial Transplant. 2007;22:911-916.
15. Beltowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit. 2006;12:RA112-RA119.
16. Time Magazine. 1944-04-10. http://www.time.com/time/magazine/article/0, 9171, 796530, 00.html. Accessed May 20, 2009.
17. Becker GJ, Hewitson TD. "Relaxin and renal fibrosis." Kidney Int. March 2001;59:1184-1185.
18. Wilkinson TN, Speed TP, Tregear GW, Bathgate RA. "Evolution of the relaxin-like peptide family." BMC Evol Biol. February 2005;5:14.
19. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
20. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
21. Papadopoulos DP, Makris TK. "Masked hypertension- definition-impact-outcomes a critical review." J Clin Hypertens (Greenwich). 2007;9:956-963.
22. Shimbo D, Newman JD, Schwartz JE. Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass: the Masked Hypertension Study. Am J Hypertens. 2012;25:664-671.
23. Sharman JE, Hare JL, Thomas S, et al. Association of masked hypertension and left ventricular remodeling with the hypertensive response to exercise. Am J Hypertens. 2011;24:898-903.
24. Hänninen MR, Niiranen TJ, Puukka PJ, et al. Determinants of masked hypertension in the general population: the Finn-Home study. J Hypertens. 2011;29:1880-1888.
25. Charles CJ. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovasc Hematol Agents Med Chem. 2007;5:1-10.
26. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34-41.
27. Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxidedependent mechanism. Regul Pept. 2001;99:87-92.
28. Ishida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem. 2004;279:26274-26279.
29. Falcão-Pires I, Castro-Chaves P, Miranda-Silva D, et al. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov Today. 2012;17:880-889.
30. Sonmez A, Celebi G, Erdem G, et al. Plasma apelin and ADMA Levels in patients with essential hypertension. Clin Exp Hypertens. 2010;32:179-183.
31. Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens. 2011;29:971-979.
32. Sherwood O. Relaxin's physiological roles and other diverse actions. Endocrinol Rev. 2004;25:205-234.
33. Conrad KP, Novak J. The emerging role of relaxin in renal and cardiovascular function. Am J Physiol. 2004;287:R250-R261.
34. Bani D, Bigazzi M. Relaxin as a cardiovascular drug: a promise kept. Curr Drug Saf. 2011;6:324-328.
35. Tanaka M. Relaxin-3/insulin-like peptide 7, a neuropeptide involved in the stress response and food intake. FEBS J. 2010;277:4990-4997.
36. Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev. 2009;14:321-329.
37. Xu Q, Chakravorty A, Bathgate RA, et al. Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats. Hypertension. May 2010;55:1260-1266.
38. Gedikli O, Yilmaz H, Kiris A, et al. Circulating levels of relaxin and its relation to cardiovascular function in patients with hypertension. Blood Press. 2009;18:68-73.